A S Coates
Reply to Does the expert panel at the St Gallen meeting provide an unbiased opinion about the management of women with early breast cancer?
Coates A, Goldhirsch A, Gelber R, Ingle J, Thürlimann B, Senn H. Reply to Does the expert panel at the St Gallen meeting provide an unbiased opinion about the management of women with early breast cancer?. Ann Oncol 2019; 20:1751-1752.
04.12.2019Reply to Does the expert panel at the St Gallen meeting provide an unbiased opinion about the management of women with early breast cancer?
04.12.2019Ann Oncol 2019; 20:1751-1752
Coates A S, Goldhirsch A, Gelber R D, Ingle J N, Thürlimann Beat, Senn H-J
Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT
Regan M, Goldhirsch A, Coates A, Gelber R, Abdi E, Ruhstaller T, Parmar V, Spazzapan S, Salim M, Pinotti G, Tondini C, Colleoni M, Gómez H, Láng I, Fleming G, Francis P, Walley B, Pagani O. Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT. Ann Oncol 2017; 28:2225-2232.
01.09.2017Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT
01.09.2017Ann Oncol 2017; 28:2225-2232
Regan M M, Goldhirsch A, Coates A S, Gelber R D, Abdi E A, Ruhstaller Thomas, Parmar V, Spazzapan S, Salim M, Pinotti G, Tondini C, Colleoni M, Gómez H L, Láng I, Fleming G F, Francis P A, Walley B A, Pagani O
Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial
Munzone E, Colleoni M, Goldhirsch A, Coates A, Gelber R, Price K, Lelkaitis G, Bibeau F, Macgrogan G, Ejlertsen B, Thürlimann B, Viale G, Mallon E, Gusterson B, Giobbie-Hurder A, International Breast Cancer Study Group and the BIG 1-98 Collaborative Group. Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial. Ann Oncol 2015
19.09.2015Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial
19.09.2015Ann Oncol 2015
Munzone E, Colleoni M, Goldhirsch A, Coates A S, Gelber R D, Price K N, Lelkaitis G, Bibeau F, Macgrogan G, Ejlertsen B, Thürlimann Beat, Viale G, Mallon E, Gusterson B A, Giobbie-Hurder A, International Breast Cancer Study Group and the BIG 1-98 Collaborative Group
-Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
Coates A, Winer E, Goldhirsch A, Gelber R, Gnant M, Piccart-Gebhart M, Thürlimann B, Senn H, Panel members. -Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol 2015; 26:1533-46.
04.05.2015-Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
04.05.2015Ann Oncol 2015; 26:1533-46
Coates A S, Winer E P, Goldhirsch A, Gelber R D, Gnant M, Piccart-Gebhart M, Thürlimann Beat, Senn H-J, Panel members
Symptoms of endocrine treatment and outcome in the BIG 1-98 study
Huober J, Thürlimann B, Gelber R, Colleoni M, Coates A, Goldhirsch A, Price K, Wardley A, Smith I, Láng I, Neven P, Forbes J, Bonnefoi H, Ejlertsen B, Wu J, Giobbie-Hurder A, Rabaglio M, Cole B, BIG 1-98 Collaborative and International Breast Cancer Study Groups. Symptoms of endocrine treatment and outcome in the BIG 1-98 study. Breast Cancer Res Treat 2013; 143:159-69.
05.12.2013Symptoms of endocrine treatment and outcome in the BIG 1-98 study
05.12.2013Breast Cancer Res Treat 2013; 143:159-69
Huober J, Thürlimann Beat, Gelber R D, Colleoni M, Coates A S, Goldhirsch A, Price K N, Wardley A, Smith I, Láng I, Neven P, Forbes J F, Bonnefoi H, Ejlertsen B, Wu J, Giobbie-Hurder A, Rabaglio M, Cole B F, BIG 1-98 Collaborative and International Breast Cancer Study Groups
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
Goldhirsch A, Winer E, Coates A, Gelber R, Piccart-Gebhart M, Thürlimann B, Senn H, Panel members. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 2013; 24:2206-23.
04.08.2013Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
04.08.2013Ann Oncol 2013; 24:2206-23
Goldhirsch A, Winer E P, Coates A S, Gelber R D, Piccart-Gebhart M, Thürlimann Beat, Senn H-J, Panel members
Prognosis of medullary breast cancer: analysis of 13 International Breast Cancer Study Group (IBCSG) trials
Huober J, Regan M, Gelber R, Price K, Öhlschlegel C, Viale G, Coates A, Goldhirsch A, Gelber S, Thürlimann B. Prognosis of medullary breast cancer: analysis of 13 International Breast Cancer Study Group (IBCSG) trials. Ann Oncol 2012; 23:2843-51.
14.06.2012Prognosis of medullary breast cancer: analysis of 13 International Breast Cancer Study Group (IBCSG) trials
14.06.2012Ann Oncol 2012; 23:2843-51
Huober Jens, Regan M M, Gelber R D, Price K N, Öhlschlegel Christian, Viale G, Coates A S, Goldhirsch A, Gelber S, Thürlimann Beat
Subjective cognitive complaints one year after ceasing adjuvant endocrine treatment for early-stage breast cancer
Ribi K, BIG 1-98 Collaborative Group, Bernhard J, Gelber R, Price K, Goldhirsch A, Coates A, Pagani O, Cardoso F, Thürlimann B, Harvey V, Thompson A, Phillips K, Aldridge J, International Breast Cancer Study Group. Subjective cognitive complaints one year after ceasing adjuvant endocrine treatment for early-stage breast cancer. Br J Cancer 2012; 106:1618-25.
24.04.2012Subjective cognitive complaints one year after ceasing adjuvant endocrine treatment for early-stage breast cancer
24.04.2012Br J Cancer 2012; 106:1618-25
Ribi K, BIG 1-98 Collaborative Group, Bernhard J, Gelber R D, Price K N, Goldhirsch A, Coates A S, Pagani O, Cardoso F, Thürlimann Beat, Harvey V, Thompson A, Phillips K-A, Aldridge J, International Breast Cancer Study Group
Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
Goldhirsch A, Wood W, Coates A, Gelber R, Thürlimann B, Senn H, Panel members. Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011; 22:1736-47.
27.06.2011Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
27.06.2011Ann Oncol 2011; 22:1736-47
Goldhirsch A, Wood W C, Coates A S, Gelber R D, Thürlimann Beat, Senn H-J, Panel members
Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial
Viale G, Thürlimann B, Mouridsen H, Mauriac L, Gelber R, Price K, Goldhirsch A, Gusterson B, Coates A, Láng I, Colleoni M, Regan M, Dell'orto P, Mastropasqua M, Maiorano E, Rasmussen B, Macgrogan G, Forbes J, Paridaens R, for the BIG 1-98 Collaborative and International Breast Cancer Study Groups. Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial. Ann Oncol 2011; 22:2201-2207.
18.02.2011Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial
18.02.2011Ann Oncol 2011; 22:2201-2207
Viale G, Thürlimann Beat, Mouridsen H, Mauriac L, Gelber R D, Price K N, Goldhirsch A, Gusterson B A, Coates A S, Láng I, Colleoni M, Regan M M, Dell'orto P, Mastropasqua M G, Maiorano E, Rasmussen B B, Macgrogan G, Forbes J F, Paridaens R J, for the BIG 1-98 Collaborative and International Breast Cancer Study Groups
Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial
Rabaglio M, Coates A, Goldhirsch A, Gelber R, Smith I, Láng I, Nogaret J, Pienkowski T, Colleoni M, Paridaens R, Forbes J, Campone M, Mouridsen H, Thürlimann B, Hawle H, Castiglione-Gertsch M, Price K, Sun Z, BIG 1-98 Collaborative and International Breast Cancer Study Groups. Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial. Ann Oncol 2009; 20:1489-98.
01.09.2009Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial
01.09.2009Ann Oncol 2009; 20:1489-98
Rabaglio M, Coates A S, Goldhirsch A, Gelber R D, Smith I, Láng I, Nogaret J-M, Pienkowski T, Colleoni M, Paridaens R J, Forbes J F, Campone M, Mouridsen H, Thürlimann Beat, Hawle H, Castiglione-Gertsch M, Price K N, Sun Z, BIG 1-98 Collaborative and International Breast Cancer Study Groups
Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009
Goldhirsch A, Ingle J, Gelber R, Coates A, Thürlimann B, Senn H, Panel members. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009; 20:1319-29.
01.08.2009Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009
01.08.2009Ann Oncol 2009; 20:1319-29
Goldhirsch A, Ingle J N, Gelber R D, Coates A S, Thürlimann Beat, Senn H-J, Panel members
The effect of endocrine responsiveness on high-risk breast cancer treated with dose-intensive chemotherapy: results of International Breast Cancer Study Group Trial 15-95 after prolonged follow-up
Colleoni M, Goldhirsch A, Price K, Viale G, Aebi S, Cinieri S, Peccatori F, Green M, Gelber R, Coates A, Basser R, Martinelli G, Sun Z, International Breast Cancer Study Group. The effect of endocrine responsiveness on high-risk breast cancer treated with dose-intensive chemotherapy: results of International Breast Cancer Study Group Trial 15-95 after prolonged follow-up. Ann Oncol 2009; 20:1344-51.
01.08.2009The effect of endocrine responsiveness on high-risk breast cancer treated with dose-intensive chemotherapy: results of International Breast Cancer Study Group Trial 15-95 after prolonged follow-up
01.08.2009Ann Oncol 2009; 20:1344-51
Colleoni M, Goldhirsch A, Price K N, Viale G, Aebi S, Cinieri S, Peccatori F, Green M D, Gelber R D, Coates A S, Basser R L, Martinelli G, Sun Z, International Breast Cancer Study Group
Adverse prognostic value of peritumoral vascular invasion: is it abrogated by adequate endocrine adjuvant therapy? Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy for early breast cancer
Viale G, Goldhirsch A, Gelber R, Öhlschlegel C, Karlsson P, Crivellari D, Golouh R, Brown R, Price K, Regan M, Castiglione-Gertsch M, Colleoni M, Mallon E, Sonzogni A, Mastropasqua M, Maiorano E, Gusterson B, Giobbie-Hurder A, Coates A. Adverse prognostic value of peritumoral vascular invasion: is it abrogated by adequate endocrine adjuvant therapy? Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy for early breast cancer. Ann Oncol 2009; 21:245-54.
24.07.2009Adverse prognostic value of peritumoral vascular invasion: is it abrogated by adequate endocrine adjuvant therapy? Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy for early breast cancer
24.07.2009Ann Oncol 2009; 21:245-54
Viale G, Goldhirsch A, Gelber R D, Öhlschlegel Christian, Karlsson P, Crivellari D, Golouh R, Brown R W, Price K N, Regan M M, Castiglione-Gertsch M, Colleoni M, Mallon E, Sonzogni A, Mastropasqua M G, Maiorano E, Gusterson B A, Giobbie-Hurder A, Coates A S
Extracapsular tumor spread and the risk of local, axillary and supraclavicular recurrence in node-positive, premenopausal patients with breast cancer
Gruber G, Gusterson B, Viale G, Goldhirsch A, Price K, Coates A, Gelber R, Fey M, Simoncini E, Thürlimann B, Crivellari D, Collins J, Golouh R, Lindtner J, Holmberg S, Castiglione-Gertsch M, Cole B, International Breast Cancer Study Group. Extracapsular tumor spread and the risk of local, axillary and supraclavicular recurrence in node-positive, premenopausal patients with breast cancer. Ann Oncol 2008; 19:1393-401.
01.08.2008Extracapsular tumor spread and the risk of local, axillary and supraclavicular recurrence in node-positive, premenopausal patients with breast cancer
01.08.2008Ann Oncol 2008; 19:1393-401
Gruber G, Gusterson B A, Viale G, Goldhirsch A, Price K N, Coates A S, Gelber R D, Fey M F, Simoncini E, Thürlimann Beat, Crivellari D, Collins J, Golouh R, Lindtner J, Holmberg S B, Castiglione-Gertsch M, Cole B F, International Breast Cancer Study Group
Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy?
Regan M, SOFT/TEXT/PERCHE Steering Committee, Gelber R, Goldhirsch A, Coates A, Castiglione-Gertsch M, Maibach R, Thürlimann B, Price K, Fleming G, Francis P, Perez E, Torrisi R, Walley B, Pagani O, International Breast Cancer Study Group. Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy?. Ann Oncol 2008; 19:1231-41.
01.07.2008Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy?
01.07.2008Ann Oncol 2008; 19:1231-41
Regan M M, SOFT/TEXT/PERCHE Steering Committee, Gelber R D, Goldhirsch A, Coates A S, Castiglione-Gertsch M, Maibach R, Thürlimann Beat, Price K N, Fleming G F, Francis P, Perez E A, Torrisi R, Walley B, Pagani O, International Breast Cancer Study Group
Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer
Bernhard J, Coates A, Goldhirsch A, Price K, Castiglione-Gertsch M, Gelber R, Colleoni M, Green M, Thürlimann B, Yeo W, Aebi S, Forbes J, Hürny C, Basser R, Martinelli G, Zhang J, Zahrieh D, International Breast Cancer Study Group. Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer. BJC 2008; 98:25-33.
15.01.2008Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer
15.01.2008BJC 2008; 98:25-33
Bernhard J, Coates A S, Goldhirsch A, Price K N, Castiglione-Gertsch M, Gelber R D, Colleoni M, Green M D, Thürlimann Beat, Yeo W, Aebi S, Forbes J F, Hürny C, Basser R, Martinelli G, Zhang J J, Zahrieh D, International Breast Cancer Study Group
Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007
Goldhirsch A, Wood W, Gelber R, Coates A, Thürlimann B, Senn H, 10th St. Gallen conference. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007; 18:1133-44.
01.07.2007Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007
01.07.2007Ann Oncol 2007; 18:1133-44
Goldhirsch A, Wood W C, Gelber R D, Coates A S, Thürlimann Beat, Senn H-J, 10th St. Gallen conference
Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial
Mauriac L, Castiglione-Gertsch M, Price K, Coates A, Smith I, Viale G, Rabaglio M, Zabaznyi N, Goldhirsch A, BIG 1-98 Collaborative Group, Gelber R, Nogaret J, Keshaviah A, Debled M, Mouridsen H, Forbes J, Thürlimann B, Paridaens R, Monnier A, Láng I, Wardley A, International Breast Cancer Study Group. Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial. Ann Oncol 2007; 18:859-67.
01.05.2007Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial
01.05.2007Ann Oncol 2007; 18:859-67
Mauriac L, Castiglione-Gertsch M, Price K N, Coates A S, Smith I, Viale G, Rabaglio M, Zabaznyi N, Goldhirsch A, BIG 1-98 Collaborative Group, Gelber R D, Nogaret J-M, Keshaviah A, Debled M, Mouridsen H, Forbes J F, Thürlimann Beat, Paridaens R, Monnier A, Láng I, Wardley A, International Breast Cancer Study Group
CA15-3 and alkaline phosphatase as predictors for breast cancer recurrence: a combined analysis of seven International Breast Cancer Study Group trials
Keshaviah A, Coates A, Gelber R, Castiglione Gertsch M, Simoncini E, Pagani O, Price K, Aebi S, Mendiola C, Thürlimann B, Colleoni M, Collins J, Crivellari D, Lindtner J, Rotmensz N, Dellapasqua S, Goldhirsch A. CA15-3 and alkaline phosphatase as predictors for breast cancer recurrence: a combined analysis of seven International Breast Cancer Study Group trials. Ann Oncol 2007; 18:701-8.
01.04.2007CA15-3 and alkaline phosphatase as predictors for breast cancer recurrence: a combined analysis of seven International Breast Cancer Study Group trials
01.04.2007Ann Oncol 2007; 18:701-8
Keshaviah A, Coates A S, Gelber R D, Castiglione Gertsch M, Simoncini E, Pagani O, Price K N, Aebi S, Mendiola C, Thürlimann Beat, Colleoni M, Collins J, Crivellari D, Lindtner J, Rotmensz N, Dellapasqua S, Goldhirsch A